BR112022000971A2 - Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv - Google Patents

Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv

Info

Publication number
BR112022000971A2
BR112022000971A2 BR112022000971A BR112022000971A BR112022000971A2 BR 112022000971 A2 BR112022000971 A2 BR 112022000971A2 BR 112022000971 A BR112022000971 A BR 112022000971A BR 112022000971 A BR112022000971 A BR 112022000971A BR 112022000971 A2 BR112022000971 A2 BR 112022000971A2
Authority
BR
Brazil
Prior art keywords
hbv
treatment
induced diseases
hbv infection
dihydropyrimidine derivatives
Prior art date
Application number
BR112022000971A
Other languages
English (en)
Inventor
Chao Liang
Gang Deng
Jianping Wu
Linglong Kong
Xiangjun Deng
Yanping Xu
Yimin Jiang
Zhanling Cheng
Zhiguo Liu
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of BR112022000971A2 publication Critical patent/BR112022000971A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv. são fornecidos derivados de di-hidropirimidina que são úteis no tratamento ou prevenção de infecção por hbv ou de doenças induzidas por hbv, mais particularmente de infecção crônica por hbv ou de doenças induzidas por infecção crônica por hbv, bem como suas aplicações farmacêuticas ou médicas.
BR112022000971A 2019-07-31 2020-07-30 Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv BR112022000971A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019098569 2019-07-31
CN2020077163 2020-02-28
CN2020096777 2020-06-18
PCT/CN2020/105764 WO2021018237A1 (en) 2019-07-31 2020-07-30 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Publications (1)

Publication Number Publication Date
BR112022000971A2 true BR112022000971A2 (pt) 2022-06-07

Family

ID=74230289

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000971A BR112022000971A2 (pt) 2019-07-31 2020-07-30 Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv

Country Status (11)

Country Link
US (1) US20230083012A1 (pt)
EP (1) EP4003355A4 (pt)
JP (1) JP2022542420A (pt)
KR (1) KR20220041120A (pt)
CN (1) CN114173787A (pt)
AU (1) AU2020323092A1 (pt)
BR (1) BR112022000971A2 (pt)
CA (1) CA3146992A1 (pt)
MX (1) MX2022001261A (pt)
TW (1) TW202122392A (pt)
WO (1) WO2021018237A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39616A (es) * 2021-01-29 2022-07-29 Janssen Sciences Ireland Unlimited Co Derivados de dihidropirimidina y usos de estos en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
WO2022257942A1 (en) 2021-06-09 2022-12-15 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012823A1 (de) * 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
CN101575318B (zh) * 2009-06-25 2012-02-08 中国人民解放军军事医学科学院毒物药物研究所 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途
US9487534B2 (en) * 2011-08-02 2016-11-08 Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California Modulators of virus assembly as antiviral agents
RU2014142598A (ru) * 2012-03-31 2016-05-27 Ф. Хоффманн-Ля Рош Аг Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
CN104926808B (zh) * 2012-08-24 2018-09-14 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CN103664897B (zh) * 2012-09-01 2018-04-03 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CN103664925B (zh) * 2012-09-07 2018-01-23 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
CN103664899B (zh) * 2012-09-11 2017-06-16 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
EA030115B9 (ru) * 2014-03-07 2018-09-28 Ф. Хоффманн-Ля Рош Аг Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
JP6710642B2 (ja) * 2014-05-30 2020-06-17 チル ファーマシューティカル カンパニー リミテッド Ｈｂｖ阻害剤としてのジヒドロピリミジン縮環誘導体
SG10201912847QA (en) * 2015-03-16 2020-02-27 Hoffmann La Roche Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
WO2017064156A1 (en) * 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
AR107633A1 (es) * 2016-02-19 2018-05-16 Hoffmann La Roche Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
ES2894605T3 (es) * 2016-09-13 2022-02-15 Hoffmann La Roche Tratamiento combinado con un agonista de TLR7 y un inhibidor del ensamblaje de la cápside del VHB
CN107501257B (zh) * 2017-08-17 2020-05-29 山东大学 二氢嘧啶-三氮唑类衍生物及其制备方法与应用
CN108947996B (zh) * 2018-07-12 2022-01-18 山东大学 二氢嘧啶-磺酰胺类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
TW202122392A (zh) 2021-06-16
EP4003355A4 (en) 2023-07-26
JP2022542420A (ja) 2022-10-03
AU2020323092A1 (en) 2022-03-24
EP4003355A1 (en) 2022-06-01
MX2022001261A (es) 2022-05-03
WO2021018237A1 (en) 2021-02-04
US20230083012A1 (en) 2023-03-16
CN114173787A (zh) 2022-03-11
CA3146992A1 (en) 2021-02-04
KR20220041120A (ko) 2022-03-31

Similar Documents

Publication Publication Date Title
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201890006A1 (ru) Применение экзосом для лечения болезни
BR112018071585A2 (pt) formulações de um inibidor de lsd1
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112017007545A2 (pt) derivados de carbazol
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CL2016002422A1 (es) Cromeno y 1, 1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasas.
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]